Emergent BioSolutions shares dropped after the Company recorded a $191.3 million non-cash NARCAN impairment tied to naloxone competition and pricing pressure. Levi & Korsinsky is investigating potential securities law violations on behalf of EBS investors who lost money.

Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Company disclosed a $191.3 million non-cash impairment on its NARCAN franchise, attributed to increased competition and pricing pressure in naloxone. If you suffered a loss on your Emergent BioSolutions investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

NARCAN Nasal Spray is Emergent's flagship commercial product. The naloxone category has drawn multiple generic and over-the-counter entrants, and the Company previously reported a 41% year-over-year decline in fourth-quarter NARCAN revenue, attributed to increased generic competition affecting both price and unit sales, alongside a nine-percentage-point decline in commercial-products gross margin to 16%.

On February 26, 2026, an Emergent earnings presentation stated: "Maintained market leadership; pricing stabilized." The $191.3 million impairment charge tied to naloxone pricing pressure and competition was recorded approximately five months later. The investigation concerns whether the scale of Emergent's exposure to NARCAN pricing deterioration was adequately disclosed to investors.

Shareholders who lost money on EBS are encouraged to have their losses evaluated at no cost. You may also reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the EBS Investigation

Q: Who is conducting the EBS investigation? A: Levi & Korsinsky, LLP is investigating potential securities claims on behalf of investors who purchased Emergent BioSolutions securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Who is eligible to participate in the EBS investigation? A: Investors who purchased EBS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Emergent BioSolutions adequately disclosed the extent of competitive and pricing deterioration in its naloxone business, including statements that NARCAN pricing had stabilized, prior to the $191.3 million non-cash impairment.

Q: What do EBS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my EBS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EBS and sold at a loss may still participate in the investigation.

Q: What if my EBS losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.

Attorney Advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260812920779/en/